https://markets.businessinsider.com/news/stocks/avalo-therapeutics-achieves-positive-topline-results-in-phase-2-lotus-trial-of-abdakibart-avtx-009-in-moderate-to-severe-hidradenitis-suppurativa-1036108724
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart...
Successfully met primary endpoint of HiSCR75 for both doses studied, demonstrating response rates of 42.2% for 150 mg dose (p=0.018) and 42.9% for...